GenScript Biotech Corporation

Core Business

GenScript Biotech operates as an integrated CGT ecosystem spanning gene synthesis, CDMO services, and cell therapy development. In 2025, GenScript achieved $959.5 million in revenue with extraordinary 61.4% year-over-year growth. Its ProBio CDMO subsidiary experienced explosive 309.1% revenue growth to $388.7 million, driven by surging demand for plasmid DNA, viral vector manufacturing, and gene synthesis services for the global CGT industry.

Global Presence

Headquartered in Nanjing, China with US operations in New Jersey and Seattle, GenScript serves over 100 countries with 6,000+ employees. Manufacturing facilities span Nanjing, Zhenjiang (China), Hopewell (New Jersey, US), and expanding European sites. The company serves 66,000+ active customers globally through its gene synthesis and life sciences services.

Key Strengths

GenScript's unique vertically integrated business model creates powerful synergies between its research tools, CDMO, and cell therapy operations. The company's gene synthesis market leadership provides a steady customer funnel to its higher-value ProBio CDMO services. The Lights-out AI-driven factory strategy promises to reduce manufacturing costs while improving batch consistency, positioning GenScript at the forefront of CGT manufacturing automation.

VerityRank Score

GenScript Biotech achieves a VerityRank Score of 87/100, reflecting its dominant gene synthesis market position, extraordinary ProBio CDMO growth trajectory, and innovative AI-driven manufacturing strategy.